Abstract
Cytochrome P450 1B1 is a recently recognized phase I bioactivating enzyme with high affinity for both inhaled tobacco carcinogens and 17β-estradiol. We evaluated the human lung expression of this multifunctional member of the P450 superfamily across 16 individuals. Expression of CYP1B1 was evaluated by qualitative reverse transcription-polymerase chain reaction and Western immunoblots performed on human tumor and nontumor lung tissue. Expression at both mRNA and protein levels was then correlated with smoking history, plasma biomarkers of tobacco exposure (nicotine and cotinine), gender, and tumor histology. CYP1B1 mRNA and protein were detected in 94 and 100% of individuals, respectively. Multivariate analysis confirmed that there were more subjects displaying CYP1B1 mRNA expression in tumor than nontumor tissue (p = 0.0003). Correlation of CYP1B1 protein with plasma cotinine levels was statistically marginal (p = 0.027). Self-reported smoking history, gender, and tumor histology did not correlate with gene expression in the multivariate model. After multivariate modeling for confounding factors, the expression patterns of 5 of 16 individuals appeared to differ from the group as a whole for mRNA and/or protein. We conclude that CYP1B1 is commonly expressed in human lung and hypothesize that it may be an important phase I enzyme with respect to human lung carcinogen metabolism, warranting an understanding of regulatory control and coding region polymorphisms.
Footnotes
-
Send reprint requests to: Simon D. Spivack, M.D., Laboratory of Human Toxicology and Molecular Epidemiology, Wadsworth Center, NYSDOH, E624, Empire State Plaza, P.O. Box 509, Albany, NY 12201-0509. E-mail: spivack{at}wadsworth.org
-
This work was supported in part by National Institutes of Health Grant ES00298 as well as a grant from the Potts Foundation (to S.D.S.), National Institutes of Health Grant ES07462 (to X.D.), and United States Environmental Protection Agency (EPA) Grant R827180010 (to L.S.K.). The research described in this article has not been subject to the EPA's required peer and policy review and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred.
-
This work was supported in part by National Institutes of Health Grant ES00298 as well as a grant from the Potts Foundation (to S.D.S.), National Institutes of Health Grant ES07462 (to X.D.), and United States Environmental Protection Agency (EPA) Grant R827180010 (to L.S.K.). The research described in this article has not been subject to the EPA's required peer and policy review and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred.
- Abbreviations used are::
- Ahr
- aromatic hydrocarbon receptor
- RT
- reverse transcription
- PCR
- polymerase chain reaction
- bp
- base pair(s)
- P450
- cytochrome P450
- Received January 17, 2001.
- Accepted March 8, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|